Cryosurgery, a method of treating disease by the production of freezing temperatures in the tissue, is a useful technique for the treatment of tumors. When the modern era of cryosurgery began in the mid 1960's, the technique was used only for tumors easily accessible by direct observation or via endoscopy, such as those of the skin, oral cavity, and prostate gland. In general, the technique had limited usefulness in the next two decades. However, with the advent of intraoperative ultrasound as a method of monitoring the process of freezing and with the development of more effective cryosurgical apparatus, the cryosurgical treatment of tumors of the viscera and other deep tissues became practical in the 1990's. This review assesses the present day status of cryosurgery in the management of diverse tumors.
Introduction
As a result of advances in imaging techniques and minimally invasive technology, the range of usefulness of cryosurgical techniques for the treatment of tumors expanded remarkably in the 1990's. In the previous years, cryosurgery had been used only in easily accessible tumors as primary therapy with the intent to cure and for the palliation of symptoms of incurable cancer (1). The principle changes in the 1990's have been extensions of the technique used for deep-seated tumors, especially visceral tumors. At present, cryosurgery is used for diverse reasons, including use as the primary method of treatment with the intent to cure the disease, for palliation of symptoms of incurable cancer, and as an adjunct to surgical excision. This review focuses on the advances or changes in the application of cryosurgical techniques in tumors in diverse sites in the 1990's. For applications in which little change has occurred in recent years, the commentary will be brief. In sites where there has been considerable activity and new progress, comments will be of appropriate length.
Skin Cancer
Cryosurgery is an accepted technique for the treatment of skin cancers, most of which are small and are also easily treated by surgical excision and other locally destructive methods of therapy. The cryosurgical techniques for these cancers remain unchanged in the 1990's. The recent reports continue to show a success rate of 97-98% in the treatment of basal cell and squamous cell carcinomas of small size, i.e., less than 2 cm in surface diameter (2, 3). Larger lesions have a somewhat lesser success rate and require more extensive freezing. Aggressive freezing techniques have yielded good results in the treatment of recurrent basal cell carcinomas (4). Cryosurgery is best suited for tumors with well-defined borders. When the borders of the cancer are poorly defined, an alternate method of treatment, such as Mohs' micrographic surgery, is a better choice.
Most skin cancers are superficial as well as small, so the amount of tissue requiring destruction is rather little in comparison with cancers elsewhere. Hand-held devices providing a spray of liquid nitrogen are used. Most physicians rely on clinical judgment only to control freezing, even though the use of thermosensors to confirm the adequacy of treatment has been strongly recommended. Though ultrasound can be used to monitor freezing in the skin, such use is unlikely in clinical practice because of added costs. Nevertheless, the development of new devices may permit progress in ultrasound or MRI monitoring of cryosurgery for skin tumors (5, 6) . Special note must be made of recent reports on the use of cryosurgery for the treatment of basal cell carcinomas of the eyelids. In one report, a high cure rate, that is, with no recurrent disease, was noted in 92 patients studied for five years and longer (7) . A more recent report stated that the recurrence rate in patients studied for five years or longer was 5.1% of 220 patients (8) . The authors considered this result to be superior to excisional surgery and considered cryosurgery to be a low cost option to micrographic surgery. The cosmetic results were termed excellent. Similar outcomes and conclusions were reached by Tupparainen (9) , as well as by Gunnarson and associates (10) .
Advanced incurable cancers of the skin, recurrent after surgical extension and/or radiotherapy, have been treated by cryosurgical techniques for palliation of symptoms. The benefits include reduction of tumor bulk, relief of pain, and reduction of malodorous discharge. Aggressive freezing has produced occasional impressive results in a few selected patients with advanced skin cancer or cancers involving the skin, including the breast and vulva. These techniques have not changed in the 1990's.
As far as cutaneous melanoma is concerned, cryosurgery has no role in attempted cure. The best treatment for melanoma is excision, which provides a specimen for histopathological examination, though small lesions could be destroyed easily by freezing in situ and precursor lesions have been treated by cryosurgery (11, 12) . Advanced melanoma has occasionally been treated by cryosurgery, sometimes looking for immunologic-based benefit. A recent report, describing the treatment of mucosal and cutaneous melanoma by cryosurgery alone or in combination with radiotherapy and hyperthermia, concluded that the combined therapy was beneficial (13).
Eye Tumors
Interest in the usefulness of cryosurgery in the management of tumors of the eye began in the modern era of cryosurgery and has matured in the 1990's. Cryosurgery has proven useful in the treatment of retinoblastoma, the common primary tumor of the eye in children. In past years, enucleation of the eye has been the standard treatment, but the frequency of bilateral tumors encourages efforts to save at least one eye. Therefore, in recent years, alternative treatments, such as radiotherapy, photocoagulation, and cryosurgery, have become useful. Shields (14) has defined the indications for cryosurgery, described successful treatment of 53 of 67 tumors (79%), and concluded that cryosurgery was an effective method of management of selected cases of retinoblastoma. Eichler and Frauenfelder (15) found cryosurgery useful in the treatment of conjunctival lymphoid tumors. Twelve patients with 42 lymphoid tumors who were treated with liquid nitrogen spray, were managed successfully, though often repeated treatments were needed.
Application of cryosurgical techniques to other orbital tumors has not been of significant benefit except when used as an adjunct to surgical excision or in the management of disease recurrent after surgical excision. Cryosurgery as adjunctive therapy after surgical excision seemed to be of benefit in 62 cases of conjunctival melanosis and malignant melanoma as described by Jakobiec and his associates (16). Exenteration was avoided in patients with unifocal nodules of malignant melanoma, but those patients with multinodular malignant melanoma were a difficult therapeutic problem, often developing metastatic disease. The use of cryosurgery or excision with adjunctive cryosurgery has yielded a significant benefit in ocular melanomas and squamous neoplasia of the conjunctiva (16) (17) (18) (19) (20) . Cryo-assisted excision, that is, using the cold cryosurgical probe to facilitate excision of orbital tumors, has been confirmed as a useful technique by several recent reports (21-24).
In summary, though the place of cryosurgery in the management of tumors of the eye is limited, a range of usefulness has been developed, perhaps largely as an adjunct to surgical excision.
Brain Tumors
Tumors of the brain are commonly treated by surgical excision, radiotherapy or chemotherapy. Cryosurgery had a limited trial at the beginning of the modern era of cryosurgery, but little progress was possible because neuroimaging techniques were not well developed. Advances in imaging techniques stimulated interest in cryosurgery. In 1992, Maroon and his associates (25) reported on the cryosurgical treatment of 71 patients with diverse types of tumors of the brain, spinal cord and orbit. Cryosurgery was used to facilitate surgical excision in 64 patients, and was used to destroy residual tumor after incomplete excision in several patients. The cryo-assisted excision facilitated the operation. The cryoablation procedures were successful, at least as judged in a short-term follow-up. Judging from this and other reports, cryo-assisted excision of tumors of the brain and spinal cord is an effective technique (26, 27) . The value of cryosurgery for brain tumors appears to be only as an adjunct to surgical excision.
Oral Cancers
Cancers of the oral cavity are treated by excision or radiotherapy, often with adjunctive chemotherapy. The diversity of clinical manifestations creates room for consideration of cryosurgery in selected patients, especially those who are at high risk or have disease persistent after other therapy, as described in reports in the 1970's and 1980's, which suggested some usefulness for this cancer (28). However, rather few reports have described the use of cryosurgery for oral cancer recently. Tanaka (29) includes the treatment of 46 patients with oral cancer in his extensive experience with tumors in diverse sites. In the 26 patients treated primarily with cryosurgery, a 5-year survival rate of about 63% was achieved. Palliative benefits were achieved in the 20 patients treated for recurrent disease. Li (30) described the cryosurgical treatment of 50 patients with cancer of the tongue. In a follow-up period of 3 to 10 years, the survival rate was 70% but the recurrence rate was 10%, and a number of patients died with cervical lymph node metastases, which became evident after cryosurgery. The report endorsed the use of cryosurgery for selected oral cancers, but pointed out the need to plan treatment of the regional lymph nodes, even though no metastatic disease is evident, a concern which long has been discussed in the management of oral cancer.
A report by Akine and associates (31) , from the National Cancer Center in Tokyo, on the treatment of carcinoma of the anterior two-thirds of the tongue in 244 patients, stage-II disease, all previously untreated, compared irradiation, surgical excision, and cryosurgery in management. Cryosurgery was chosen for those patients with superficially spreading tumors or those in poor general health. The local control rate was similar in all therapies and the five-year survival rate was about 70% for every method of treatment. Cryosurgery was recommended for those patients with superficial cancers, that is, those measuring 5mm or less in thickness.
Some investigators have focused on the use of cryosurgery to treat recurrent oral cancer and cancer of the pharynx when other methods of treatment have failed. This salvage therapy, combining cryosurgery with a radiotherapy and chemotherapy, has yielded occasional long-term survival of patients with difficult cancers involving the oral cavity, oropharynx and nasopharynx. For example, Meyza and Towpik (32) , in patients with oral and oropharyngeal cancer persisting or recurring after radiotherapy, attempted salvage by cryosurgery in 29 patients refusing major surgery. The selected patients had persistent tumors of about 2 cm or less in diameter and were in accessible locations. Seven of 29 patients were free of tumors after 3-11 years follow-up. Often only palliative benefits were provided, but these can be significant in terms of reduction in tumor size and restoration of function.
Occasional use in other oral tumors has been described. Hemangiomas in the oral mucosa are easy to treat by freezing in situ. Melanomas are ordinarily excised, but cryosurgical treatment has been reported to provide benefit (29). Scala and his associates (13) treated three patients with melanomas of the hard palate and achieved complete remission of the local lesion.
Conservation of bone of the oral cavity and suitability for the high-surgical-risk patient are reasons why cryosurgery deserves consideration in the management of oral cancer. Nevertheless, at this time, physicians show little interest in the use of cryosurgery for oral cancer. Years ago it appeared that cryosurgery would develop a place in the treatment of oral cancers and offer the opportunity to avoid bone-sacrificing operations. That has not occurred and only the occasional cases of the types just cited reflect current practice.
Cancer Of The Pharynx And Larynx
Pharyngeal cancers readily infiltrate the adjacent tissues and are not easily treated by surgical techniques. In general, radiotherapy and chemotherapy are chosen for management. Experience with cryosurgery is small, certainly scant since 1990. In their report on 62 patients who had surgical and cryosurgical salvage therapy, Meyza and Towpik (32) included seven patients with tonsillar cancer treated by cryosurgery. Three of the seven were listed as cured. The most favorable area in the pharynx for attempted salvage by cryosurgery is the tonsillar area because of relative ease of accessibility to a cryosurgical probe in comparison to the other pharyngeal areas. In a report difficult to evaluate because of the multiplicity of treatments, Sheng and Jia (33) reported on 49 patients with nasopharyngeal cancer who were treated with diverse therapies, including cryosurgery in 25 patients. Only 20 patients were followed for more than 3 years; 60% survived that interval.
Cancer of the larynx is best treated by surgical excision or radiotherapy. Cryosurgery has practically no applicability to early cancers because of the difficulty in identifying the extent of disease and, after freezing, the threat to the airway from edema and necrotic tissue. The clinical trials in early and advanced cancers, initiated in the 1970's, have not continued in recent years. Benign tumors, especially hemangiomas and lymphangiomas, in the pharynx and larynx, have been treated with cryosurgery, often combined with other techniques, such as laser or radiotherapy, with some success (34-37).
Bronchial Tumors
Cryosurgery has no certain place in the treatment of early bronchial cancer. Some clinical trials have investigated freezing techniques to treat bronchial epithelial dysplasia and carcinoma in situ. Deygas and associates (38) reported their experience in the treatment via bronchoscopy of early superficial bronchogenic carcinoma in 35 patients. Local recurrence within 4 years was noted in 10 patients (28%). The authors state that their results suggest that cryosurgery is an effective method of treatment for this condition. On the other hand, Sheski and Mathur (39) have expressed the opinion that the data on cryosurgery or alternate bronchoscopic therapies is insufficient to judge merit for this disease.
Cryosurgery is of value in incurable bronchial cancer. Advanced bronchial tumors threaten life by airway obstruction, hemorrhage and infection. Endobronchial therapy can palliate symptoms and may prolong life. The options in palliative endobronchial therapy are multiple, which suggests that no one therapy fits all clinical circumstances (40) (41) (42) (43) . With regard to cryosurgery, the major clinical application has been for the relief of tracheobronchial obstruction to inoperable cancer. The technique and results from freezing of the obstructing tumor via bronchoscopy are well described in a recent textbook and in a recent review (44, 45) . Maiwand and Homasson (46) , physicians experienced with this technique, report benefits, including relief of dyspnea, cough, stridor and hemoptysis, in about 70% of 800 patients with inoperable tracheobronchial cancer. Pulmonary function tests improved in 30-40% of patients. The elimination of the airway obstruction by cryosurgery avoided local complications, improved survival, and permitted safer and more effective radiotherapy.
Mathur and his associates (47) described fiber optic bronchoscopic cryotherapy in the management of tracheobronchial obstruction. In a series of 20 patients, the obstruction was relieved in 90%. In another report, the treatment of 38 patients with advanced cancer, cryosurgery was applied to the obstructing tumor, and then followed with radiotherapy. Local control of tumor growth was achieved in 17 of 26 patients in whom cryosurgery had reduced the endobronchial residual tumor. The results suggested that irradiation was more effective after cryosurgical reduction of obstruction and that the results of radiotherapy are thereby improved (48).
Marasso and his associates (49) reported the cryosurgical treatment of 234 patients with tracheobronchial stenosis due to malignant (183 patients) and nonmalignant disease (51 patients) and achieved such benefits as reduction in hemoptysis in 94% and lessening of dyspnea in 81%. Later, this same group of physicians described radio frequency resection of bronchial tumors in combination with cryosurgery (50). In this technique, the radio frequency resection was used to clear the lumen and the cryosurgery was used to treat the residual tumor in the bronchial wall. The bronchial lumen was opened by at least 80% in about 80% of patients. A lesser degree of benefit was provided in about 20% of patients.
In summary, experience with bronchoscopic cryotherapy has broadened since 1990. A large number of patients with obstructing bronchial lesions, mostly cancer, have been treated and have noted palliative benefits in terms of opening the airway, lessening of dyspnea and control of hemoptysis. The benefits are achieved over several days, which is slower than laser therapy. However, cryosurgery is safer, less costly, and yields more favorable healing.
Cancer of the Lung
For more advanced cancers of the lung, whether extensions of bronchial cancer or metastatic from other tissues, the need for a thoracotomy to provide access to the tumor and the difficulty in observing the effects of therapy inhibit consideration of cryosurgery. Rather little experience has been reported on cryosurgery for tumors of the lung in recent years. Generally the extent of the disease precludes any benefit from surgical therapy. However, a report from China describes cryosurgical treatment of pulmonary metastasis in 112 patients from 1973 to 1993 (51). The five-year survival rate was 28%. Often, the cryosurgery was combined with anaerobic corynebacterium vaccine given as an immunopotentiator. The authors concluded that cryosurgical resection was safe and effective. Nevertheless, the prospects for benefit from cryosurgery in these conditions seem slim.
Tumors of the Esophagus
Cryosurgery has little or no place in the treatment of tumors of the esophagus. In the 1960's and 1970's, a limited experience showed that obstruction due to advanced cancer could be relieved and palliation be achieved. The cryosurgical treatment was given via endoscopy and repeated every three months to maintain the esophageal lumen. Though effective, cryosurgery is rarely used for this disease because alternative therapeutic techniques, including laser therapy and intraluminal stents, provide quicker palliation.
Tumors of the Liver
Primary and secondary tumors of the liver are best managed by excision, which provides the possibility of long survival and the chance of cure. Unfortunately, the large majority of cancers of the liver, whether primary or secondary to cancers in other organs, are not suitable for surgical excision. Such patients are candidates for alternate methods of treatment, including cryosurgery.
Early in the modern era of cryosurgery, that is, in the mid 1960's and 1970's, considerable interest in hepatic cryosurgery was manifest, but little clinical use was practical because the lack of useful imaging techniques precluded clinical development. Interest in the cryosurgical treatment of liver tumors was stimulated by the demonstration of the feasibility of monitoring the process of tissue freezing by ultrasound (52). Then cryosurgery, now practical, came into clinical use for tumors of the liver in the 1990's.
Cryosurgery is used for liver tumors in diverse clinical circumstances. Most commonly, cryosurgery has been used for patients who have tumors considered unresectable because of lesions in more than one lobe of the liver, or because of proximity to major blood vessels. Cryosurgery also has been chosen in patients with severe associated disease, especially cirrhosis, because of high surgical risk. Often cryosurgery has been combined with excisional surgery, excising some lesions while freezing other lesions in situ (53, 54) . The number, size and location of the tumors are factors influencing the choice of therapy. Cryosurgery has been used also when the line of excision has transected the tumor, leaving disease in the margin of the wound (55). The remaining tumor is treated by freezing the surface of the wound. Cryosurgery has been used to assist excisional techniques achieve a safe margin. After excision, the resection edge is treated by cryosurgery with the expectation of reducing the incidence of recurrent disease (56-58).
Another use of cryosurgery is termed cryo-assisted excision, a method in which the cryoprobe is used to facilitate excision of a tumor. The probe is inserted into the tumor and is cooled to produce freezing. The frozen volume is maintained during excision of the frozen tissue. The technique provides a method of gaining traction on a tumor to facilitate removal or reduce bleeding during excision or provides the possibility of excision of a geometrically shaped volume of tissue (59, 60). Cryo-assisted excision also reduces the chance that cancer cells will spread during manipulation. This technique has been shown to be valuable in the removal of tumors in several sites, including the brain, the eye, the breast, and the liver.
The placement of the cryosurgical probes in the tumor has been done most commonly via laparotomy, which provides the best opportunity to evaluate the extent of disease. Recently laparoscopic and percutaneous techniques have been used with a good measure of success (61, 62). After evaluation, the subsequent procedure depends on the extent of disease. Extra-hepatic spread of tumor precludes the possibility of benefit from cryosurgery. The selected treatment varies widely, including various combinations of cryosurgery and excision. Wherever cryosurgery is used, optimal freezing technique includes repeated freeze-thaw cycles, which increase the certainty of cell destruction (63-65). In high-surgical-risk patients, cryosurgery may be chosen for all of the lesions. Many surgeons will set the maximum number of lesions to six, but considerable variation in practice exists and a diversity of opinion about size, number, and location of lesions in relation to suitability for cryoabla-tion is evident in clinical practice. However, clearly the extent of freezing, that is, the volume of frozen tissue, influences the incidence of postoperative complications; the greater the volume of hepatic tissue frozen, the more likely the development of postoperative problems (66).
Postoperative complications occur in about 20% of patients (67). Complications characteristic of hepatic cryosurgery include depressed platelet counts and prolonged coagulation. These changes are in proportion to the volume of liver frozen. The term cryoshock has come into use to describe the syndrome of disseminated intravascular coagulation and multiorgan failure that occurs after cryosurgery, generally after freezing large volume of tissues. Cytokine release is likely the cause of cryoshock (68). Nevertheless, in general, the mortality after hepatic cryosurgery is low, that is, in the 1 to 4% range.
The results of cryosurgery are generally favorable in selected cases, whether used for primary liver tumors or metastatic tumors. In the treatment of primary liver cancers, the long experience of Zhou and associates (69) has been noteworthy. Cryosurgery was used for patients with severe liver cirrhosis, in whom resection was contraindicated, for patients with residual tumor after incomplete excision, and for patients with recurrent disease after excision. In 235 patients, a 5year survival rate of 39.8% was achieved, so the procedure was judged to be safe and effective. Similar conclusions have been reached by other investigators (70).
In the treatment of cancer that is metastatic to the liver, which commonly is colorectal in origin, the excellent review by Seifert et al. (71) provides considerable data on many aspects of hepatic cryosurgery. Generally, one might expect to achieve a two-year survival rate of about 25 to 40%, depending on case selection. However, the incidence of recurrence at the cryo-treated site is commonly 20-40%, more in some reports, less in others (72-75). This recurrence reflects less than optimal treatment, which may be due to faulty judgment regarding the extent of the disease, inadequate tissue freezing, or the need for improved monitoring techniques. The incidence of recurrence also points out the need for adjunctive therapy.
Commonly, chemotherapy is used with cryosurgery, but the choice of drug and time and method of delivery is an unsettled matter. Preketes and associates (76) achieved increased survival in patients with liver metastases from colorectal cancer treated by cryosurgery when adjunctive chemotherapy was given via the hepatic artery. In a later report on 116 patients treated by cryosurgery and intra-arterial chemotherapy, Seifert and Morris (77) reported a 2-year survival rate of 56%, which was a distinct improvement in survival apparently due to the drug. Most often however, cancer chemotherapeutic drugs are given systemically (71, 73, (78) (79) (80) and should be used with a measure of caution because their use in full doses immediately after cryosurgery may aggravate the problems of coagulopathy after cryosurgery.
In summary, cryosurgery for liver tumors is a safe, effective method of treatment when surgical excision is not possible or needs some assistance in treatment. Cryosurgery extends the curative potential of excisional surgery and in addition has the potential to increase survival in selected patients with unresectable tumors. Adjunctive therapy with cancer chemotherapeutic drugs will increase survival.
Tumors of the Pancreas
The possible application of cryosurgery to pancreatic cancer has aroused interest for several years. Practically all reports on pancreatic cryosurgery consist of work with animals, and state that limited pancreatic freezing can be done without mortality and that the effect on the pancreas features an inflammatory response including a sharp rise in serum pancreatic enzyme levels for several days, followed by progressive changes ending in complete destruction of the normal architecture and healing with fibrous tissue formation (81-83). These diverse reports all expressed the opinion that cryosurgery might be applicable to pancreatic cancer. Nevertheless, clinical experience with freezing the pancreas is sparse and most of it can be found in Russian literature, which focuses primarily on freezing the pancreas for pancreatitis (84). Experience with pancreatic cancer is very limited. Patiutko and colleagues (85) used cryosurgery and irradiation in 30 patients with locally advanced pancreatic cancer. The benefits were relief of pain and prolonged survival. Kovach et al. (86) performed 10 cryosurgical procedures in 6 patients with unresectable pancreatic cancer. No operative morbidity or mortality resulted. All patients benefited from good pain control with some assistance from drug therapy. Nevertheless, clinical application for pancreatic cancer is not likely. Presumably, curable cancers will be excised. For incurable cancer, one can consider cryosurgery directed at denervation of the organ in order to relieve pain.
Tumors of the Kidney
The application of cryosurgical techniques to the treatment of kidney tumors is rather early in development. The successful use of ultrasound imaging to monitor cryosurgical ablation of tumors in the prostate and liver encouraged consideration of use in the kidney, especially when conservation of kidney function was critical to the patient. In patients with marginal functional reserve of the kidney, partial nephrectomy is a therapeutic option. In a similar manner, cryosurgery offers the possibility of conserving renal tissue.
An excellent experimental study pertinent to renal cryosurgery was reported by Barone and Rodgers in 1988 (87) .
Cryogenic lesions were produced in rabbits with a probe 1 cm in diameter cooled to a temperature of -180º C. A tissue temperature of -40º C was produced 1 cm deep in the renal parenchyma in the cooling periods of about 10 to 11 minutes. The rather large cryogenic lesions were associated with transient gross hematuria and some disturbance of renal function, but the animals tolerated the injury well. The cryolesion which originally resembled a hemorrhagic infarct involving 50% of the kidney, matured in about eight weeks to a contracted small fibrous scar. They suggested that cryosurgery may prove useful in the treatment of renal tumors. Gill, Novick and associates (88) reported on laparoscopic cryosurgery in 32 patients. The criteria for selection for cryosurgery were based on the need to conserve renal tissue because of age and associated disease and a tumor less than 4 cm in diameter. Via a laparoscopic approach, either retroperitoneal or transperitoneal, the tumor was frozen with a double freeze-thaw cycle, taking care to extend the frozen zone about 1 cm beyond the periphery of the tumor. The results were excellent in this early report. A CT-guided biopsy of the treated area showed no evidence of tumor on any patient.
Open renal cryosurgical approach was described by Rukatalis, Khorsandi, and associates (89) who reported on 29 patients with kidney tumors, malignant and benign, treated by cryosurgery through a subcostal incision. The lesions ranged in size from 1.0 to 4.6 cm (median 2.7 cm). One to three probes (size 3 or 8 mm) were inserted into the lesion. A double freeze-thaw cycle, monitored by ultrasound and at times with a thermosensor placed at the periphery of the lesion, was used. The goal was to reach -40º C at the periphery of the lesion. Five patients had bleeding from the fissured kidney in the thawing period. In the postoperative follow-up, one patient had persistent renal cell carcinoma. Three patients, more than 6 months after treatment, developed renal failure, requiring dialysis. The investigators concluded that open renal cryoablation was a safe procedure.
Current experience continues to demonstrate the efficacy of cryosurgery for small renal tumors. Magnetic resonance imaging has come into use as a monitoring technique that offers some advantages over other imaging methods (90, 91) . Smaller cryoprobes cooled by argon are quite suited to percutaneous use (92, 93) . In recent reports, cryosurgery of small renal tumors continues to show promise as longterm results mature. The laparoscopic approach appears to be safe and effective (93) (94) (95) (96) .
Cancer of the Prostate
Cryosurgery for prostatic disease, first used in the mid 1960's, almost abandoned in the mid 1970's, has had a renaissance in the 1990's for the treatment of cancer of the prostate (97). The new enthusiasm was due to the use of ultrasound to monitor the freezing process, to the development of technologically advanced cryosurgical equipment, and to the technique of transperineal placement of probes. As the next few years passed, improvements in technique featured the use of warming catheters to protect the urethra and its sphincter, increased use of temperature monitoring at the periphery of the gland, and protection of the rectum from freezing injury (98-100). New types of cryogenic apparatus, featuring thinner cryoprobes placed through a brachytherapy template, came into use (101). The result may prove to be improved efficacy of prostate cryosurgery, even though pressurized argon in a Joule-Thomson apparatus does not have the tissue-freezing capability of liquid nitrogen. Compensation for this deficiency is gained by the use of more probes.
Diverse patient selection criteria have been used, so cryosurgery has been applied to every stage of the disease, including advanced cancer with the intent to achieve palliative benefits. Cryosurgery has been used also for patients with persistent disease after irradiation. As is true for the other methods of treatment, patients with the early stages of cancer have the best chance of cure. Reducing the size of the gland by androgen ablation therapy in the preoperative period is a common practice.
The technique requires the placement of multiple cryoprobes in the prostate through the perineum (100-102). The freezing is performed in a manner that shapes the frozen tissue in conformity with the prostate gland. Ultrasound guidance of the freezing process has well known problems with distortions and shadows, so the use of thermocouples in conjunction with ultrasound increases the control of the therapy (103, 104). The appropriate temperature to produce in the prostate is -40º C or colder. In the prostate, this is difficult to achieve at the periphery of the gland because of the proximity of the rectum. Fortunately, repetitions of the freeze-thaw cycle will increase the injury at somewhat warmer temperatures, probably at about -20º C. However, considerable variation in the way that cryosurgery is applied in practice is evident. This is a source of concern. The causes of failure were analyzed by Izawa and associates (105) , who showed the need for at least two freeze-thaw cycles and multiple cryoprobe usage. This review of 150 patients who had persistent prostate cancer after irradiation, then were treated by cryosurgery, showed the difficulty in adequately freezing the prostate.
The results of cryosurgery have gradually improved as physicians gained greater experience with the treatment.
The major complications that result from prostatic cryosurgery are impotence, incontinence, and urethrorectal fistulas. Impotence is an outcome of the treatment if the entire prostate is frozen. Onik and his associates have made an effort to preserve the neurovascular bundle by treating only the side of the prostate which had proven cancer (106). The outcome of this effort remains to be determined. Rukstalis, et al. (107) , in a study of radical prostatectomy specimens, found multifocal cancer in 79.5% of specimens, which should dampen enthusiasm for focal prostatic cryoablation. In addition, the study showed that 66% of cases had cancer within 5mm of the urethra. This fact raises questions about the safety of the use of the urethral warming catheter in terms of allowing the survival of peri-urethral cancer.
A multicenter report on the use of argon-cooled probes, placed in the prostate with the aid of a brachytherapy template, described the results in 106 patients (108). The usual array of minor complications followed cryosurgery, but no fistulas developed. In follow-up of 12 months, 75% did not have persistent disease as measured by PSA determination. Longer follow-up is clearly needed in this investigation.
Donnelly and associates (104) reported on 76 patients in several stages of the disease. Though 10 patients had residual cancer after the first cryosurgical treatment, repeated treatment was effective. The overall survival rate was cited as 89%. When this was broken down in terms of risk level of the disease, the survival rate appeared favorably comparable to other methods of therapy. A similar conclusion was reached in the multi-institutional reports (108, 109).
Experience with salvage cryosurgery for persistent prostatic cancer after radiotherapy is generally favorable, though obviously this is a difficult type of disease. Ghafar et al. (110) , treating 38 men with persistent cancer, achieved biochemical recurrence-free survival of 74% at the two-year interval. On the reverse side of the coin, it is interesting that salvage radiotherapy after failure of cryosurgical ablation is possible (111, 112) .
In summary, cryosurgery for prostatic cancer is a safe effective procedure which produces results favorably comparable to other methods of treatment. Nevertheless the incidence of persistent disease demonstrates that the technique is not yet optimal. Greater attention must be given to the production of tissue-lethal temperatures in the gland. The proximity of the prostate gland to the rectum makes the procedure more difficult, but the sharp decrease in the incidence of rectal fistulas indicates that treatment is becoming more controlled. The use of thermocouples to measure tissue temperature has been a notable improvement in technique. Even now the long-term results of prostatic cryosurgery need maturation before evaluation of efficacy.
Tumors of Bone
Experiments in animals have shown that bone, devitalized by freezing in situ is repaired by a slow process of resorption and revascularization to gradually form new bone. The devitalized bone matrix serves as a scaffold for repair (113, 114) . Extensive cryogenic injury was often associated with fracture of the weakened bone during the weeks required for healing. Clinical application to the treatment of bone tumors followed the experimental work.
In general, cryosurgical techniques have been applied to benign bone tumors, such as giant cell tumors and ameloblastomas, which are locally aggressive and prone to resurgence after curettage. Application of cryosurgery for sarcomas of bone or cancers metastatic to bone has been limited.
In the treatment of bone tumors, cryosurgery is an adjunct to curettage of the tumor. After curettage, the resultant cavity is frozen, which devitalizes an additional centimeter of bone around the tumor site, perhaps thereby increasing the chance of cure. The freezing is done by direct application of liquid nitrogen, pouring or spraying the cryogen into the bone cavity or by application of a cryoprobe. When the cryosurgical treatment is complete, the bone cavity is reinforced with bone grafts or acrylic cement (115). Because of bone weakness consequent to the tumor and its treatment, bone support (casts, braces, or intramedullary rods, etc.) is desirable to reduce the chance of fracture. The healing is very slow and the principal complication is fracture of the weakened bone. Details on the technique are well described by Bickels and associates (116) .
Cryosurgery has been used most commonly for giant cell tumors of bone (116) (117) (118) (119) . Of these several reports, that of Malawer and associates (118) described a large multicenter experience with 102 patients with giant cell tumors. In an average follow-up of 6.5 years, the rate of local recurrence in 86 patients treated previously by cryosurgery was 2.3%. The investigators concluded that cryosurgery had advantages of joint preservation and excellent functional outcome. A higher recurrence rate was reported by Boons and associates (119) who described good functional results but concluded that more vigorous freezing was needed to improve local tumor control. Clearly two freeze-thaw cycles are needed for bone tumors, just as are needed for tumors anywhere (120).
Other types of bone tumors treated by curettage and cryosurgery include ameloblastomas, chondrosarcomas, and metastatic carcinomas (120-124). Curi et al. (121) treated 36 patients with ameloblastomas of the jaw with curettage and cryosurgery. They achieved a local recurrence rate of 30.6% in a follow-up of 1-10 years. This is better than can be achieved by curettage alone. Sampson and Pogrel (122) , reported no recurrence in a smaller number of patients.
Sarcomas and metastatic carcinomas in diverse sites, including the sacrum, also respond well to curettage and cryosurgery (123, 124) . Relief of pain is commonly immediate after cryosurgery.
In summary, curettage and adjunctive cryosurgery increases the chance of cure in selected patients with bone tumors. The technique is most commonly used in benign or locally aggressive tumors, such as giant cell tumors and ameloblastomas. The technique may also provide palliative benefits, especially relief of pain in other malignant bone tumors. It should be noted that cryosurgical techniques are useful in benign disease of bone, such as fibrous dysplasia and cysts.
Breast Tumors
Breast tumors are best treated by complete surgical excision. However, in view of current-day interest in the diverse minimally invasive techniques of treating breast tumors, it is not surprising to find cryosurgery under consideration (125, 126) . The use of cryosurgery for breast cancer was suggested by Rand and his associates in 1985 (127, 128) . After some experimental work with a mouse mammary tumor, they exposed by incision a breast cancer in an elderly woman, subjected the tumor to repeated freeze-thaw cycles, then excised the tumor while still frozen. Rather little was done with this application, at least as far as clinical use is concerned, for several years.
Experiments with animals have shown that cryosurgery is applicable to breast tissue. The effects of freezing breast tissue in an animal model shows the usual process of injury and repair. The experiments of Hong and Rubinsky (129) showed that a measure of resistance to water loss is produced by tightly packed malignant cells of breast cancer and that the morphology also caused intracellular freezing at low cooling rates. In their experiments, fat cells, which contain little water, lost little volume in freezing. Fat, in comparison to other tissue, has a low thermal conductivity. Therefore, the frozen volume of tissue will be smaller in fatty tissue then in non-fatty tissue in similar freezing cycles. The insulating effect of fat is important in any tumor located in fatty tissue. In experimental model, the thermal parameters needed, including a double freeze-thaw cycle, are the same as needed for any tumor (130). The process of injury and repair are the same as in any tissue (131).
In 1977, Staren and his associates reported a well-designed experimental study which showed the feasibility of destroying small carcinogen-induced adenocarcinomas in rats and demonstrated the importance of achieving a lethal tissue temperature (-40º C or colder) and the enhanced destructive effect of prolonged freezing and repetition of the freezing cycle (132). In large animals (dogs and sheep), the feasibility of monitoring the frozen tissue in the breast was demon-strated. In a patient, the authors then used cryosurgery to treat two small tumors in the right breast. With ultrasound guidance, the cryosurgical probe was placed into the tumor and repeated freeze-thaw cycles were used. The second tumor was treated in the same way. Then leaving the devitalized tumor in situ, the wounds were closed.
The two instances of application to breast cancers in humans, cited in the two experimental reports, demonstrate the manner in which cryosurgery could be developed for breast cancer lesions. In the first instance, termed "cryolumpectomy", the tumor was frozen, then excised in the frozen state. This is a form of cryo-assisted excision, a technique which has been useful in tumors of the brain, the eye, the liver, and other organs. The second instance, freezing the tumor in situ and allowing the devitalized tissue to remain in place, is truly cryoablation, as is true of cryoablative techniques in other tissues.
Trials of cryosurgery for early breast cancer are few. Pfleiderer and associates (133) treated 15 patients with ultrasound-guided cryosurgery. Necrosis of the tumor was incomplete in 11 of the 15 patients. The investigators realized that more aggressive freezing, perhaps with multiple probes, was needed.
Ultrasound-guided cryosurgery has been used successfully for benign lesions of the breast. In 50 patients with fibroadenomas of the breast, Kaufman et al. (134) achieved good results and cryoablation of these lesions was considered a good alternative to excision.
Trials in humans of the several ablative techniques, including cryosurgery, for breast tumors continue. However, it seems unlikely that cryosurgery, at least in the form of leaving the frozen tissue in place, will prove popular, principally because no specimen is available for histologic examination. On the other hand, cryo-assisted excision may prove to be a valuable technique.
In the management of advanced incurable breast cancer, cryosurgery has a long history. Early in the modern era of cryosurgery, Gill and his associates (135) used cryosurgery for palliation in 20 patients with recurrent, post-excision breast cancer. The principal benefit was relief of pain. In the 1990's, similar benefits have been described by others. In experience extending over many years, Tanaka (136) treated 49 cases with advanced incurable breast cancer and achieved benefits, including prolonged survival rate, in 44%. Suzuki (137) described the treatment of eight patients with advanced breast cancer, incurable because of distant metastases. The benefits included reduction in tumor bulk, control of pain, and possibly some benefit provided by cryoimmunologic responses (regression of contralateral breast cancer and lymph node metastases). Sugiyama and associates (138) combined cryosurgery with concurrent use of the immunopotentiator OK-432 and in some patients, chemotherapy also, and achieved benefits in terms of control of growth of the tumor. The investigators concluded that their results favored the use of cryosurgery in combination with the local injection of OK-432 and favored also augmentation by chemotherapeutic drugs.
From these and other reports (139, 140) , it is clear that cryosurgery can reduce tumor bulk and relieve distressing symptoms in inoperable advanced cancers. The question of immunologic benefit remains open to proof in clinical cases but is a provocative subject.
Tumors in Other Sites
Tumors in diverse, less common sites have been treated by cryosurgery for many years, sometimes for a cure, other times for palliation of distressing symptoms. Those tumors that have been treated with the intent to cure include penile and vulvar cancers, glomus jugular tumors, chordomas, neuromas, hemangiomas, thyroid tumors, and leiomyomas (1, 28, 29, 141, 142) . Experience in these tumors is limited to rather few cases.
Palliative cryosurgery is sometimes beneficial in advanced cancers, providing benefits related to reduction in tumor bulk. Typical benefits are described in the recent report of Meijer et al. (143) who provided information on cryosurgery as palliative treatment in 106 patients with unresectable rectal cancer. Relief of obstruction and control of bleeding and discharge were achieved. Periodic re-treatment was required to maintain control of the tumor. Inoperable cancers in diverse sites can be managed by cryosurgery. Palliative benefits can also be provided by other methods of treatment, each of which has its own advantages and disadvantages. Cryosurgery should be considered in many problems in the management of tumors.
Summary
Cryosurgical techniques, born in 1850, modernized with automated equipment in the mid 1960's, entered a period of relative inactivity in the 1980's, and were revitalized in the 1990's by the development of new technology. Currently cryosurgery has found application to tumors in diverse sites, but greatest interest is in tumors of the skin, bronchus, liver, kidney, prostate, and bone. The range of usefulness in visceral sites is extended by minimally invasive techniques. Advances in imaging techniques are expected to improve the monitoring of the freezing process, but a better application of optimal freezing techniques is critical to achieving improved results. In a large measure, progress is dependent upon the further development of temperature measurement technology, especially in non-invasive techniques, and on the use of adjunctive therapy. 
